RESUMO
Because of their clinical and neuroradiological features, tumefactive demyelinating lesions, or giant plaques, are easily mistaken for tumors, with a consequent risk of gross errors in the choice of treatment. This article reports a 10-year-old girl who underwent surgery for a left parietal lesion misinterpreted as a glioblastoma which subsequently proved to be a case of giant plaque.
Assuntos
Encefalopatias/diagnóstico , Neoplasias Encefálicas/diagnóstico , Doenças Desmielinizantes/diagnóstico , Gliossarcoma/diagnóstico , Lobo Parietal , Encefalopatias/patologia , Encefalopatias/cirurgia , Edema Encefálico/diagnóstico , Edema Encefálico/patologia , Edema Encefálico/cirurgia , Neoplasias Encefálicas/patologia , Neoplasias Encefálicas/cirurgia , Criança , Corpo Caloso/patologia , Doenças Desmielinizantes/patologia , Doenças Desmielinizantes/cirurgia , Erros de Diagnóstico , Feminino , Gliossarcoma/patologia , Gliossarcoma/cirurgia , Humanos , Imageamento por Ressonância Magnética , Estadiamento de Neoplasias , Exame Neurológico , Lobo Parietal/patologia , Lobo Parietal/cirurgia , Tomografia Computadorizada por Raios XRESUMO
PURPOSE: To discuss the results obtained by giving adjuvant treatment for childhood ependymoma (EPD) at relapse after complete surgery only. METHODS AND MATERIALS: Between 1993 and 2002, 63 children older than 3 years old entered the first Italian Association for Pediatric Hematology and Oncology protocol for EPD (group A), and another 14 patients were referred after relapsing after more tumor excisions only (group B). Prognostic factors were homogeneously matched in the two groups. We report on the outcome of group B. RESULTS: Mean time to first local progression in group B had been 14 months. Tumors originated in the posterior fossa (PF) in 10 children and were supratentorial (ST) in 4; 11 had first been completely excised (NED) and 3 had residual disease (ED). Diagnoses were classic EPD in 9 patients, anaplastic in 5. Eight children were referred NED and 6 ED after two or more operations, 5 had cranial nerve palsy, 1 had recurrent meningitis, and 2 had persistent hydrocephalus. All received radiotherapy (RT) to tumor bed and 5 also had pre-RT chemotherapy. Six of 14 patients (6/10 with PF tumors) had a further relapse a mean 6 months after the last surgery; 4 of 6 died: progression-free survival and overall survival at 4 years after referral were 54.4% and 77%, respectively. Considering only PF tumors and setting time 0 as at the last surgery for group B, progression-free survival and overall survival were 32% and 50% for group B and 52% (p < 0.20)/70% (p < 0.29) for the 46 patients in group A with PF tumors. Local control was 32% in group B and 70.5% in group A (p = 0.02). CONCLUSIONS: Relapsers after surgery only, especially if with PF-EPD, do worse than those treated after first diagnosis; subsequent surgery for tumor relapse has severe neurologic sequelae.
Assuntos
Neoplasias Encefálicas/radioterapia , Ependimoma/radioterapia , Terapia de Salvação/métodos , Adolescente , Neoplasias Encefálicas/tratamento farmacológico , Neoplasias Encefálicas/cirurgia , Quimioterapia Adjuvante , Criança , Pré-Escolar , Ependimoma/tratamento farmacológico , Ependimoma/cirurgia , Feminino , Humanos , Neoplasia Residual , Radioterapia Adjuvante , Resultado do TratamentoRESUMO
PURPOSE: The aim of this study was to avoid radiotherapy and to induce an objective response in children with low-grade glioma (LGG) using a simple chemotherapy regimen based on cisplatin and etoposide. PATIENTS AND METHODS: Thirty-four children (median age, 45 months) with unresectable LGG were treated with 10 monthly cycles of cisplatin (30 mg/m(2)/d on days 1 to 3) and etoposide (150 mg/m(2)/d on days 1 to 3). Tumor originated in the visual pathway in 29 patients, in the temporal lobe in two, in the frontal lobe in two, and in the spine in one. Eight children were affected by neurofibromatosis type 1. Objective tumor response and toxicity were evaluated by magnetic resonance imaging and neurologic and functional tests at 3-month intervals. RESULTS: An objective response was obtained in 24 (70%) of 34 patients, whereas the others had stable disease. None of the children were electively irradiated. In 31 previously untreated children, overall survival was 100% and progression-free survival was 78% at 3 years, with a median follow-up of 44 months. Acute toxicity was unremarkable; 28% patients evaluated for acoustic neurotoxicity revealed a loss of perception of high frequencies. CONCLUSION: Cisplatin and etoposide combined treatment is one of the most active regimens for LGG in children and allows avoidance of radiotherapy in the vast majority of patients.